Canaccord initiated coverage of GeneDx (WGS) with a Buy rating and $155 price target The company has undergone a “significant” financial turnaround, driven by its shift to high-value exome and genome testing, the analyst tells investors in a research note. The firm says GeneDx’s leading position in the “underpenetrated market” of newborn screening and its long-term opportunity in adult testing could support solid near- and long-term performance.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WGS:
- WGS, PONY, QSI, SLMT: Cathie Wood Snaps Up Biotech and AI Stocks, Trims Stake in a Semiconductor Name
- GeneDx announces Mimi Lee as chief precision medicine officer
- GeneDx selected by Florida State University as partner for Sunshine Genetics Act
- DASH, DE, BABA: Cathie Wood Loads Up on DoorDash, Deere & Alibaba, Trims Stakes in ADPT and Others
- GeneDx appoints Gurry as Chief Business Officer